AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

This study is exploring a new way to treat colorectal cancer that has spread to the liver. Researchers want to see if adding an experimental drug called AK104 and targeted radiotherapy to standard chemotherapy works better than chemotherapy alone. AK104 is a type of immunotherapy designed to help your immune system recognize and attack cancer cells by blocking specific proteins that usually keep the immune system in check.

To join this study, you must have colorectal cancer with liver metastases that cannot be surgically removed at this time. This trial is for patients who have not yet received treatment for their advanced disease, or those who finished past treatment at least six months ago. You should be in relatively good health and able to perform daily activities. You may not be eligible if you have a history of autoimmune diseases, certain heart conditions, or if you have previously received immunotherapy treatments like PD-1 or CTLA-4 inhibitors.

If you participate, you will be randomly assigned to either receive the standard chemotherapy or the combination of chemotherapy, AK104 infusions, and radiation directed at a liver tumor. Before enrolling, you should talk to your doctor about your complete medical history, especially any history of lung inflammation, infections, or organ transplants, as these may affect your safety during the trial.